Advanced Tissue Sciences receives patent for growing living cartilage with mesenchymal stem cells.
The newly issued patent is complementary to the company's patent 5,842,477 entitled "Method for Repairing Cartilage," which issued in December of 1998. This method patent covers use of a three-dimensional scaffold along with cartilage-producing cells and a periosteal flap to repair a defect in vivo. The company's current patent position now includes 50 issued United States patents directly owned by or licensed to Advanced Tissue Sciences.
"The issuance of our cartilage patents is timely as we advance toward clinical trials," said Gail K. Naughton, PhD, president and chief operating officer. "Two-year follow-up on our preclinical trials on small animal models, preclinical studies in a large animal model, and our strengthened patent position make us, together with our joint venture partner, Smith & Nephew, well poised to advance the orthopedic products."
On April 15, 1999 Advanced Tissues Sciences was awarded a Small Business Innovation Research Program grant from the Department of Health and Human Services, Public Health Services. This grant, entitled "Enhancing In Vitro Cartilage Synthesis for Human Therapy," will fund development of a bioreactor that applies mechanical stresses to growing cartilage. The bioreactor is designed to stimulate matrix deposition to affect the organizational, structural, and functional properties of cartilage growth. Work funded by this grant is directed at the development of cartilage products for reconstructive applications.
Advanced Tissue Sciences is a tissue engineering company utilizing its proprietary core technology to develop and manufacture human-based tissue products for tissue repair and transplantation. The company, through its Dermagraft Joint Venture with Smith & Nephew, currently has two products on the market, TransCyte(TM), a temporary covering for third-degree (full- thickness) and second-degree (partial-thickness) burns, and Dermagraft, a living dermal replacement for the treatment of diabetic foot ulcers (currently available in Canada and the United Kingdom). The company is conducting a multi-center trial for Dermagraft for treating diabetic foot ulcers in the United States and is pursuing additional indications for Dermagraft, including venous and pressure ulcers through the Dermagraft Joint Venture. The company is also developing products for cartilage and cardiovascular applications.
|Printer friendly Cite/link Email Feedback|
|Comment:||Advanced Tissue Sciences receives patent for growing living cartilage with mesenchymal stem cells.|
|Publication:||BIOTECH Patent News|
|Date:||May 1, 1999|
|Previous Article:||IntraTherapeutics signs licensing agreement with American BioMed for Vascular embolization microfilter technology.|
|Next Article:||Incyte Prevails on Preliminary Injunction Request.|